<DOC>
	<DOC>NCT01281592</DOC>
	<brief_summary>This is an open-label, phase 1 study to determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.</brief_summary>
	<brief_title>A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours</brief_title>
	<detailed_description />
	<criteria>1. Male or female 18 years of age or older. 2. Histologically confirmed diagnosis of solid tumour for which no effective therapy is available or that is unresponsive to conventional therapy. 3. Meet laboratory parameter requirements at study entry. 1. Chemotherapy, radiotherapy, biologic therapy, immunotherapy or any other investigational drugs within 21 days of beginning study treatment with LOR253 HCl. 2. A hematologic malignancy. 3. A history of brain or other central nervous system metastases. 4. Have a presence of a significant infection. 5. Clinically significant autoimmune disease. 6. Uncontrolled intercurrent illness. 7. With iron or copper overload syndromes. 8. Pregnancy or breast feeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>